在一线 (1L) 转移性非鳞状非小细胞肺癌 (NSCLC) 中使用派姆单抗维持治疗奥拉帕尼或维持治疗培美曲塞的研究 (MK-7339-006, KEYLYNK-006)
Pembrolizumab 联合培美曲塞/铂类药物(卡铂或顺铂)的 3 期研究,随后是 Pembrolizumab 和维持奥拉帕尼对比维持培美曲塞一线治疗转移性非鳞状非小细胞肺癌参与者
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, versus (vs) pembrolizumab plus maintenance pemetrexed for the treatment of non-squamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent clinical review (BICR) and 2. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to overall survival (OS).
研究概览
详细说明
This study has 2 phases: an Induction Phase of up to ~4 Cycles (up to ~12 weeks [cycle =3 weeks]) and a Maintenance Phase of up to ~31 cycles of pembrolizumab (cycle = 3 weeks]); total pembrolizumab treatment duration will be up to ~35 cycles (up to ~2 years). In the Induction Phase, participants receive pembrolizumab plus pemetrexed plus platinum (carboplatin or cisplatin, at the investigator's discretion). In the Maintenance Phase, participants with a partial or complete disease response or with stable disease after completing four cycles of induction therapy and who meet eligibility criteria will be randomly assigned to receive pembrolizumab plus maintenance olaparib OR pembrolizumab plus maintenance pemetrexed. In the Maintenance Phase, participants receive pembrolizumab for up to 31 cycles (cycle = 3 weeks) plus maintenance olaparib OR maintenance pemetrexed until progressive disease (PD), intolerable toxicities, or physician decision.
Qualified participants in each study arm of the maintenance phase (Pembrolizumab plus Olaparib and Pembrolizumab plus Pemetrexed) who complete up to ~35 cycles of pembrolizumab (up to ~2 years [cycle =3 weeks]) may be eligible to receive a second course of pembrolizumab for up to ~17 cycles (up to ~1 additional year). Per protocol, response or progression during the second pembrolizumab course will not be counted towards patient reported outcomes (PROs) or efficacy outcome measures and adverse events during the second pembrolizumab course will not be counted towards safety outcome measures.
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
-
Kyiv、乌克兰、03115
- Kyiv City Clinical Oncology Centre ( Site 2210)
-
-
Cherkasy Oblast
-
Cherkasy、Cherkasy Oblast、乌克兰、18009
- Cherkasy Regional Oncology Dispensary ( Site 2211)
-
-
Dnipropetrovsk Oblast
-
Dnipro、Dnipropetrovsk Oblast、乌克兰、49102
- Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council ( Site 2201)
-
-
Ivano-Frankivsk Oblast
-
Ivano-Frankivsk、Ivano-Frankivsk Oblast、乌克兰、76018
- MI Precarpathian Clinical Oncology Center ( Site 2204)
-
-
Kharkiv Oblast
-
Kharkiv、Kharkiv Oblast、乌克兰、61024
- Grigoriev Institute for medical Radiology NAMS of Ukraine ( Site 2212)
-
Kharkiv、Kharkiv Oblast、乌克兰、61070
- CNPE "Regional Center of Oncology"-Thoracic organs ( Site 2205)
-
-
Kirovohrad Oblast
-
Kropyvnitskiy、Kirovohrad Oblast、乌克兰、25006
- PP PPC Acinus Medical and Diagnostic Centre ( Site 2209)
-
-
Kyivska Oblast
-
Khodosovka、Kyivska Oblast、乌克兰、08173
- Medical Center Asklepion LLC ( Site 2234)
-
Kyiv、Kyivska Oblast、乌克兰、03126
- Medical and Diagnostic Centre LLC Dobryi Prognoz ( Site 2213)
-
Kyiv、Kyivska Oblast、乌克兰、03039
- Medical Center Verum ( Site 2230)
-
-
Odesa Oblast
-
Odesa、Odesa Oblast、乌克兰、65055
- MI Odessa Regional Oncological Centre ( Site 2208)
-
-
Zakarpattia Oblast
-
Uzhhorod、Zakarpattia Oblast、乌克兰、88000
- Central City Clinical Hospital ( Site 2207)
-
-
-
-
Moscow
-
Moscow、Moscow、俄罗斯、115478
- Russian Oncological Research Center n.a. N.N.Blokhin of MoH ( Site 2000)
-
Moscow、Moscow、俄罗斯、119991
- First Moscow State Medical University n.a. I.M.Sechenov ( Site 2024)
-
Moscow、Moscow、俄罗斯、125284
- Moscow Research Oncology Institute named after P.A. Hertsen ( Site 2009)
-
Moscow、Moscow、俄罗斯、125367
- FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 2006)
-
-
Moscow Oblast
-
Balashikha、Moscow Oblast、俄罗斯、143900
- Moscow Regional Oncological Dispensary ( Site 2028)
-
-
Nizhny Novgorod Oblast
-
Nizhny Novgorod、Nizhny Novgorod Oblast、俄罗斯、603081
- Nizhniy Novgorod Region Oncology Dispensary ( Site 2026)
-
-
Omsk Oblast
-
Omsk、Omsk Oblast、俄罗斯、644013
- Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary-Chemotherapy #1 ( Site 2010)
-
-
Samara Oblast
-
Samara、Samara Oblast、俄罗斯、443031
- SBHI Samara Regional Clinical Oncology Dispensary ( Site 2016)
-
-
Sankt-Peterburg
-
Saint Petersburg、Sankt-Peterburg、俄罗斯、194291
- SBHI Leningrad Regional Clinical Hospital ( Site 2002)
-
Saint Petersburg、Sankt-Peterburg、俄罗斯、195271
- SPb Central Clinical Railway Hospital ( Site 2003)
-
Saint Petersburg、Sankt-Peterburg、俄罗斯、197758
- National Medical Research Center of Oncology N.A. N.N. Petrov ( Site 2004)
-
Saint Petersburg、Sankt-Peterburg、俄罗斯、198255
- SPb SBHI City Clinical Oncological Dispensary ( Site 2001)
-
-
Tatarstan, Respublika
-
Kazan'、Tatarstan, Respublika、俄罗斯、420029
- Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 2021)
-
-
-
-
British Columbia
-
North Vancouver、British Columbia、加拿大、V7L 2L7
- Lions Gate Hospital ( Site 0106)
-
Victoria、British Columbia、加拿大、V8R 6V5
- BC Cancer - Victoria ( Site 0109)
-
-
Nova Scotia
-
Halifax、Nova Scotia、加拿大、B3H 2Y9
- Queen Elizabeth II Health Sciences Centre ( Site 0107)
-
-
Ontario
-
Greater Sudbury、Ontario、加拿大、P3E 5J1
- Health Sciences North Research Institute ( Site 0115)
-
Kitchener、Ontario、加拿大、N2G 1G3
- Waterloo Regional Health Network (WRHN) ( Site 0117)
-
Newmarket、Ontario、加拿大、L3Y 2P9
- Stronach Regional Cancer Centre ( Site 0101)
-
-
Quebec
-
Greenfield Park、Quebec、加拿大、J4V 2H1
- CISSS de la Monteregie-Centre ( Site 0114)
-
Montreal、Quebec、加拿大、H3T 1M5
- CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0110)
-
Montreal、Quebec、加拿大、H2X 3E4
- Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0105)
-
Rimouski、Quebec、加拿大、G5L 5T1
- Centre de Sante et des Services Sociaux de Rimouski-Neigette ( Site 0104)
-
Sherbrooke、Quebec、加拿大、J1H 5N4
- CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0103)
-
-
-
-
-
Kaohsiung City、台湾、833
- Chang Gung Medical Foundation. Kaohsiung Branch ( Site 0907)
-
Taichung、台湾、40447
- China Medical University Hospital ( Site 0904)
-
Tainan、台湾、70457
- National Cheng Kung University Hospital ( Site 0905)
-
Taipei、台湾、104
- Mackay Memorial Hospital ( Site 0902)
-
Taipei、台湾、100
- National Taiwan University Hospital ( Site 0900)
-
Taoyuan、台湾、333
- Chang Gung Medical Foundation.Linkou Branch ( Site 0903)
-
-
-
-
Antioquia
-
Medellín、Antioquia、哥伦比亚、050030
- Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0604)
-
-
Atlántico
-
Barranquilla、Atlántico、哥伦比亚、080020
- Clinica de la Costa S.A.S. ( Site 0608)
-
-
Bogota D.C.
-
Bogotá、Bogota D.C.、哥伦比亚、110221
- Administradora Country S.A. ( Site 0603)
-
Bogotá、Bogota D.C.、哥伦比亚、111321
- Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 0601)
-
-
-
-
-
Adana、土耳其(türkiye)、01120
- Baskent Unv. Adana Uyg. ve Arast. Hastanesi ( Site 2101)
-
Ankara、土耳其(türkiye)、06500
- Gazi Universitesi Tip Fakultesi ( Site 2104)
-
Ankara、土耳其(türkiye)、06800
- Ankara Bilkent Sehir Hastanesi ( Site 2105)
-
Istanbul、土耳其(türkiye)、34093
- Bezmialem Vakif Univ. Tıp Fakultesi Hastanesi Tibbi Onkoloji Bolumu ( Site 2107)
-
Istanbul、土耳其(türkiye)、34722
- Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2103)
-
Izmir、土耳其(türkiye)、35040
- Ege Universitesi Tip Fakultesi ( Site 2109)
-
Kayseri、土耳其(türkiye)、38039
- Erciyes Universitesi Tip Fakultesi ( Site 2108)
-
Samsun、土耳其(türkiye)、55139
- Ondokuz Mayıs Universitesi-Oncology department ( Site 2106)
-
-
Tekirdas
-
Tekirdağ、Tekirdas、土耳其(türkiye)、59100
- Namik Kemal Universitesi Tip Fakultesi ( Site 2100)
-
-
-
-
-
Vienna、奥地利、1210
- Krankenhaus Nord - Klinik Floridsdorf ( Site 1300)
-
-
State of Vienna
-
Vienna、State of Vienna、奥地利、1145
- Social Medical Center - Otto Wagner Hospital ( Site 1301)
-
-
Tyrol
-
Innsbruck、Tyrol、奥地利、6020
- Innsbruck LKH ( Site 1302)
-
-
Upper Austria
-
Linz、Upper Austria、奥地利、4020
- Ordensklinikum Linz GmbH Elisabethinen ( Site 1307)
-
Wels、Upper Austria、奥地利、4600
- Klinikum Wels-Grieskirchen ( Site 1304)
-
-
-
-
-
Rio de Janeiro、巴西、20231-050
- Instituto Nacional do Cancer Jose Alencar Gomes da Silva INCA ( Site 0203)
-
São Paulo、巴西、01246-000
- Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0200)
-
São Paulo、巴西、01321-001
- BP - A Beneficencia Portuguesa de São Paulo-Medical Oncology ( Site 0214)
-
São Paulo、巴西、01321-001
- Hospital Paulistano - Amil Clinical Research ( Site 0207)
-
-
Ceará
-
Fortaleza、Ceará、巴西、60351-030
- Instituto do Cancer do Ceara ( Site 0201)
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、巴西、41253-190
- Hospital Sao Rafael ( Site 0212)
-
-
Pará
-
Belém、Pará、巴西、66053-000
- Oncologica do Brasil ( Site 0210)
-
-
Rio Grande do Sul
-
Bento Gonçalves、Rio Grande do Sul、巴西、95700-000
- Hospital Tacchini ( Site 0208)
-
Porto Alegre、Rio Grande do Sul、巴西、90050-170
- Irmandade da Santa Casa de Misericordia de Porto Alegre ( Site 0209)
-
Santa Cruz do Sul、Rio Grande do Sul、巴西、96810-110
- Saint Gallen Instituto de Oncologia ( Site 0206)
-
-
Santa Catarina
-
Florianópolis、Santa Catarina、巴西、88020-210
- YNOVA Pesquisa Clinica ( Site 0215)
-
Itajaí、Santa Catarina、巴西、88301-220
- Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 0202)
-
Joinville、Santa Catarina、巴西、89201-260
- Centro de Hematologia e Oncologia ( Site 0205)
-
-
São Paulo
-
Sao Jose Rio Preto、São Paulo、巴西、15080-000
- Hospital de Base de Sao Jose de Rio Preto ( Site 0204)
-
-
-
-
-
Hamburg、德国、22087
- Katholisches Marienkrankenhaus gGmbH ( Site 1522)
-
-
Bavaria
-
Aschaffenburg、Bavaria、德国、63739
- Studienzentrum Aschaffenburg ( Site 1525)
-
Munich、Bavaria、德国、80336
- Klinikum der LMU ( Site 1500)
-
Munich、Bavaria、德国、81925
- Klinikum Bogenhausen Staedt. Klinikum Muenchen GmbH ( Site 1523)
-
Regensburg、Bavaria、德国、93053
- Universitaetsklinikum Regensburg ( Site 1512)
-
Würzburg、Bavaria、德国、97074
- Klinikum Wuerzburg Mitte gGmbH ( Site 1509)
-
-
Hesse
-
Frankfurt am Main、Hesse、德国、60590
- Universitaetsklinikum Frankfurt ( Site 1513)
-
Immenhausen、Hesse、德国、34376
- Pneumologische Lehrklinik Universitaet Goettingen ( Site 1501)
-
-
Lower Saxony
-
Göttingen、Lower Saxony、德国、37075
- Universitaetsmedizin Goettingen ( Site 1507)
-
-
North Rhine-Westphalia
-
Bonn、North Rhine-Westphalia、德国、53127
- Universitaetsklinikum Bonn ( Site 1524)
-
Essen、North Rhine-Westphalia、德国、45136
- Kliniken Essen Mitte ( Site 1517)
-
-
Rhineland-Palatinate
-
Koblenz、Rhineland-Palatinate、德国、56068
- InVo-Institut fuer Versorgungsforschung in der Onkologie ( Site 1514)
-
-
Thuringia
-
Erfurt、Thuringia、德国、99089
- Helios Klinikum Erfurt GmbH ( Site 1502)
-
-
-
-
-
Wellington、新西兰、6021
- Capital & Coast District Health Board - Wellington Hospital ( Site 1101)
-
-
Manawatu-Wanganui
-
Palmerston North、Manawatu-Wanganui、新西兰、4414
- MidCentral DHB Palmerston North Hospital ( Site 1102)
-
-
-
-
-
Fukuoka、日本、8108563
- National Hospital Organization Kyushu Medical Center ( Site 0805)
-
Niigata、日本、951-8566
- Niigata Cancer Center Hospital ( Site 0808)
-
Okayama、日本、700-8558
- Okayama University Hospital ( Site 0810)
-
Osaka、日本、541-8567
- Osaka International Cancer Institute ( Site 0809)
-
Tokyo、日本、135-8550
- Cancer Institute Hospital of JFCR ( Site 0800)
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、460-0001
- National Hospital Organization Nagoya Medical Center ( Site 0806)
-
Nagoya、Aichi-ken、日本、464-8681
- Aichi Cancer Center ( Site 0803)
-
-
Chiba
-
Kashiwa、Chiba、日本、2778577
- National Cancer Center Hospital East ( Site 0801)
-
-
Ishikawa-ken
-
Kanazawa、Ishikawa-ken、日本、920-8641
- Kanazawa University Hospital ( Site 0811)
-
-
Kanagawa
-
Yokohama、Kanagawa、日本、241-8515
- Kanagawa Cancer Center ( Site 0807)
-
-
Miyagi
-
Sendai、Miyagi、日本、981-0914
- Sendai Kousei Hospital ( Site 0812)
-
-
Osaka
-
Hirakata、Osaka、日本、573-1191
- Kansai Medical University Hospital ( Site 0804)
-
Sakai、Osaka、日本、591-8555
- National Hospital Organization Kinki-chuo Chest Medical Center ( Site 0813)
-
-
Shizuoka
-
Suntogun、Shizuoka、日本、411-8777
- Shizuoka Cancer Center ( Site 0802)
-
-
-
-
Ain
-
Vandœuvre-lès-Nancy、Ain、法国、54519
- Institut De Cancerologie De Lorraine ( Site 1409)
-
-
Aisne
-
Chauny、Aisne、法国、02300
- Centre Hospitalier De Chauny ( Site 1411)
-
-
Calvados
-
Caen、Calvados、法国、14033
- CHU Caen ( Site 1406)
-
-
Maine-et-Loire
-
Angers、Maine-et-Loire、法国、49100
- CHU Angers ( Site 1405)
-
-
Moselle
-
Vantoux、Moselle、法国、57070
- Hopital Robert Schuman ( Site 1402)
-
-
Puy-de-Dome
-
Clermont-Ferrand、Puy-de-Dome、法国、63011
- Centre Jean Perrin ( Site 1407)
-
-
Pyrenees-Atlantiques
-
Pau、Pyrenees-Atlantiques、法国、64000
- Centre Hospitalier de Pau ( Site 1412)
-
-
Seine-Maritime
-
Rouen、Seine-Maritime、法国、76000
- CHU de Rouen ( Site 1403)
-
-
Val-de-Marne
-
Saint-Mandé、Val-de-Marne、法国、94163
- Hopital d'Instruction des Armees Begin ( Site 1413)
-
-
-
-
Greater Poland Voivodeship
-
Konin、Greater Poland Voivodeship、波兰、62-500
- Przychodnia Lekarska Komed ( Site 2416)
-
Poznan、Greater Poland Voivodeship、波兰、61-693
- MED-POLONIA Sp. z o.o. ( Site 2419)
-
-
Lesser Poland Voivodeship
-
Krakow、Lesser Poland Voivodeship、波兰、31-202
- Krakowski Szpital Specjalistyczny im Jana Pawla II ( Site 2420)
-
-
Lower Silesian Voivodeship
-
Zgorzelec、Lower Silesian Voivodeship、波兰、59-900
- Wielospecjalistyczny Szpital SPZOZ w Zgorzelcu ( Site 2404)
-
-
Masovian Voivodeship
-
Warsaw、Masovian Voivodeship、波兰、02-781
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 2418)
-
-
Silesian Voivodeship
-
Racibórz、Silesian Voivodeship、波兰、47-400
- Szpital Rejonowy im. dr Jozefa Rostka ( Site 2402)
-
-
Warmian-Masurian Voivodeship
-
Olsztyn、Warmian-Masurian Voivodeship、波兰、10-357
- Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie ( Site 2417)
-
-
-
-
New South Wales
-
Liverpool、New South Wales、澳大利亚、2170
- Liverpool Hospital ( Site 1201)
-
Wollongong、New South Wales、澳大利亚、2500
- Southern Medical Day Care Centre ( Site 1200)
-
-
Queensland
-
Townsville、Queensland、澳大利亚、4814
- Townsville General Hospital ( Site 1202)
-
-
Victoria
-
Clayton、Victoria、澳大利亚、3168
- Monash Cancer Centre ( Site 1205)
-
-
-
-
-
Brasov、罗马尼亚、500152
- Spitalul PDR Medlife ( Site 2509)
-
-
Bucharest
-
Bucharest、Bucharest、罗马尼亚、013823
- MEMORIAL HEALTHCARE INTERNATIONAL S.R.L. ( Site 2502)
-
-
Cluj
-
Cluj-Napoca、Cluj、罗马尼亚、407280
- S.C. Radiotherapy Center Cluj S.R.L ( Site 2507)
-
Cluj-Napoca、Cluj、罗马尼亚、400015
- Cardiomed SRL Cluj-Napoca ( Site 2504)
-
-
Constanța County
-
Ovidiu、Constanța County、罗马尼亚、905900
- Ovidius Clinical Hospital OCH ( Site 2501)
-
-
Dolj
-
Craiova、Dolj、罗马尼亚、200542
- S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 2508)
-
-
Timiș County
-
Timișoara、Timiș County、罗马尼亚、300239
- Policlinica Oncomed SRL ( Site 2505)
-
-
-
-
Alabama
-
Birmingham、Alabama、美国、35205
- Alabama Oncology Bruno Cancer Center ( Site 0001)
-
Muscle Shoals、Alabama、美国、35661
- Northwest Alabama Cancer Center, PC ( Site 0002)
-
-
California
-
Burbank、California、美国、91505
- Disney Family Cancer Center ( Site 0005)
-
-
Florida
-
Boca Raton、Florida、美国、33486
- Boca Raton Regional Hospital ( Site 0018)
-
Orange City、Florida、美国、32763
- Mid-Florida Cancer Centers ( Site 0022)
-
Tampa、Florida、美国、33612
- Moffitt Cancer Center ( Site 0024)
-
-
Georgia
-
Columbus、Georgia、美国、31904
- Columbus Regional Research Institute ( Site 0098)
-
-
Illinois
-
Chicago、Illinois、美国、60608
- Mount Sinai Hospital Medical Center ( Site 0032)
-
Rolling Meadows、Illinois、美国、60008
- Oncology of Northshore ( Site 0033)
-
-
Indiana
-
Merrillville、Indiana、美国、46410
- Methodists Hospitals/Premier Oncology Hematology Associates ( Site 0036)
-
-
Maryland
-
Baltimore、Maryland、美国、21239
- Medstar Good Samaritan Hospital ( Site 0040)
-
-
Michigan
-
Detroit、Michigan、美国、48201
- Barbara Ann Karmanos Cancer Institute ( Site 0041)
-
-
Mississippi
-
Hattiesburg、Mississippi、美国、39401
- Hattiesburg Clinic ( Site 0045)
-
-
Montana
-
Billings、Montana、美国、59102
- Frontier Oncology ( Site 0080)
-
Bozeman、Montana、美国、59715
- Bozeman Health Deaconness Cancer Center ( Site 0046)
-
-
North Carolina
-
Cary、North Carolina、美国、27518
- Waverly Hematology Oncology ( Site 0081)
-
-
Tennessee
-
Knoxville、Tennessee、美国、37920
- University of Tennessee Medical Center Knoxville ( Site 0060)
-
Knoxville、Tennessee、美国、37916
- Thompson Cancer Survival Center ( Site 2812)
-
-
Texas
-
The Woodlands、Texas、美国、77380
- Renovatio Clinical ( Site 0062)
-
-
Washington
-
Spokane Valley、Washington、美国、99216
- Cancer Care Northwest ( Site 0071)
-
-
-
-
-
Birmingham、英国、B9 5SS
- Birmingham Heartlands Hospital ( Site 1910)
-
-
London, City of
-
London、London, City of、英国、EC1M 6BQ
- Barts Health NHS Trust - St Bartholomew s Hospital ( Site 1923)
-
London、London, City of、英国、SW10 9NH
- Chelsea and Westminster Hospital ( Site 1901)
-
-
Suffolk
-
Bury St Edmunds、Suffolk、英国、IP33 2QZ
- West Suffolk Hospitals NHS Trust ( Site 1919)
-
-
United Kingdom
-
Edinburgh、United Kingdom、英国、EH4 2XU
- Western General Hospital, Edinburgh ( Site 1924)
-
-
Wales
-
Swansea、Wales、英国、SA2 8QA
- Singleton Hospital ( Site 1909)
-
-
Worcestershire
-
Colchester、Worcestershire、英国、CO4 5JL
- Colchester General Hospital ( Site 1911)
-
-
-
-
-
Barcelona、西班牙、08003
- Hospital del Mar ( Site 1702)
-
Seville、西班牙、41014
- Hospital Universitario Nuestra Senora de Valme ( Site 1703)
-
Zaragoza、西班牙、50009
- Hospital Clinico Lozano Blesa ( Site 1700)
-
-
Madrid
-
Pozuelo de Alarcón、Madrid、西班牙、28223
- Hospital Universitario Quiron Madrid ( Site 1701)
-
-
Valenciana, Comunitat
-
Valencia、Valenciana, Comunitat、西班牙、46010
- Hospital Clinico Universitario de Valencia ( Site 1706)
-
-
-
-
-
Córdoba、阿根廷、X5004SHP
- Clínica Universitaria Reina Fabiola ( Site 0505)
-
Santa Fe、阿根廷、S3000AOL
- Sanatorio Privado San Geronimo S.R.L ( Site 0510)
-
-
Buenos Aires
-
Bahía Blanca、Buenos Aires、阿根廷、B8001HXM
- Hospital Italiano Regional del Sur ( Site 0509)
-
Ciudad Autonoma de Buenos Aires、Buenos Aires、阿根廷、C1199ABB
- Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0511)
-
Ciudad Autónoma de Buenos Aires、Buenos Aires、阿根廷、C1280AEB
- Hospital Britanico de Buenos Aires ( Site 0500)
-
-
Córdoba Province
-
Río Cuarto、Córdoba Province、阿根廷、X5800AEV
- Instituto Medico Rio Cuarto ( Site 0501)
-
-
Santa Fe Province
-
Rosario、Santa Fe Province、阿根廷、S2000KZE
- Centro Oncológico de Rosario ( Site 0507)
-
-
Tucumán Province
-
San Miguel de Tucumán、Tucumán Province、阿根廷、T4000IAK
- Centro Medico San Roque ( Site 0506)
-
-
-
-
-
Seoul、韩国、03080
- Seoul National University Hospital ( Site 1000)
-
Seoul、韩国、08308
- Korea University Guro Hospital ( Site 1008)
-
-
Kyonggi-do
-
Goyang-si、Kyonggi-do、韩国、10408
- National Cancer Center ( Site 1006)
-
Suwon、Kyonggi-do、韩国、16247
- The Catholic University of Korea St. Vincent s Hospital ( Site 1003)
-
Suwon、Kyonggi-do、韩国、16499
- Ajou University Hospital ( Site 1004)
-
-
Kyongsangnam-do
-
Jinju、Kyongsangnam-do、韩国、52727
- Gyeongsang National University Hospital ( Site 1005)
-
-
North Chungcheong
-
Cheongju-si、North Chungcheong、韩国、28644
- Chungbuk National University Hospital ( Site 1002)
-
-
Seoul
-
Songpa-gu、Seoul、韩国、05505
- Asan Medical Center ( Site 1007)
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Have a histologically or cytologically confirmed diagnosis nonsquamous NSCLC.
-
Have stage IV nonsquamous NSCLC.
-
Have confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or Proto-oncogene tyrosine-protein kinase (ROS1)-directed therapy is not indicated.
-
Have measurable disease based on RECIST 1.1.
-
Have provided archival tumor tissue sample or newly obtained core or incisional biopsy of a tumor lesion not previously irradiated.
Note: Adequacy of biopsy specimen for the above analyses must be confirmed by the central laboratory before the participant can start the induction phase. Submission of another tumor specimen may be required prior to enrolling the participant, if adequate tumor tissue was not provided the first time.
-
Have a life expectancy of at least 3 months.
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status assessed within 7 days prior to the administration of study intervention.
-
Have not received prior systemic treatment for their advanced/metastatic NSCLC.
-
Have adequate organ function.
-
Male and female participants who are not pregnant and of childbearing potential must follow contraceptive guidance during the treatment period and for 180 days afterwards.
-
Male participants must refrain from donating sperm, and female participants must refrain from donating eggs to others or freeze/store for her own use during the treatment period and for 180 days afterwards.
Exclusion Criteria:
- Has predominantly squamous cell histology NSCLC.
- Has a known additional malignancy that is progressing or has progressed within the past 3 years requiring active treatment.
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Has a severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
- Has a known hypersensitivity to any components or excipients of cisplatin, carboplatin, pemetrexed, or olaparib.
- Has an active autoimmune disease that has required systemic treatment in past 2 years.
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy.
- Has a known history of human immunodeficiency virus (HIV) infection, a known history of hepatitis B infection, or known active hepatitis C virus infection.
- Has interstitial lung disease, or history of pneumonitis requiring systemic steroids for treatment.
- Has received prior therapy with olaparib or with any other polyadenosine 5' diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor.
- Has received prior therapy with an agent directed to programmed cell death ligand 1 (PD-L1), anti PD-L2, or directed to a stimulatory or co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), OX-40, CD137).
- Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or with features suggestive of MDS/AML.
- Has completed palliative radiotherapy within 7 days of the first dose. Participants must have recovered from all radiation-related toxicities and not require corticosteroids.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Pembrolizumab + Pemetrexed + Platinum Therapy + Olaparib
For the Induction Phase, participants receive 4 cycles (up to ~12 weeks [cycle = 3 weeks]): pembrolizumab 200 mg intravenous (IV) on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin area under the curve (AUC) 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of each cycle (Cycles 1 through 4). If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance oral olaparib 300 mg twice daily. The participant can continue to receive maintenance olaparib until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to ~35 cycles (up to ~2 years [cycle = 3 weeks]). |
IV infusion
其他名称:
Oral Tablet
其他名称:
IV infusion
其他名称:
IV infusion
其他名称:
IV infusion
其他名称:
|
|
有源比较器:Pembrolizumab + Pemetrexed + Platinum Therapy + Pemetrexed
For the Induction Phase, participants receive 4 cycles (up to ~12 weeks [cycle = 3 weeks]): pembrolizumab 200 mg IV on Day 1 of each cycle (cycles 1 through 4) PLUS pemetrexed 500 mg/m^2 IV on Day 1 of each cycle (cycles 1 through 4) PLUS platinum chemotherapy, investigator's choice: carboplatin AUC 5 mg/mL/min IV on Day 1 of each cycle (Cycles 1 through 4) OR cisplatin 75 mg/m^2 IV on Day 1 of each cycle (Cycles 1 through 4). If the participant has a complete/partial response or stable disease to induction therapy, the participant can enter the Maintenance Phase and receive pembrolizumab 200 mg IV on Day 1 of each 3-week cycle for up to 31 cycles PLUS maintenance pemetrexed 500 mg/m^2 IV on Day 1 of each 3-week cycle. The participant can continue to receive maintenance pemetrexed until progressive disease or toxicity. Across both phases, participants can receive pembrolizumab for a total treatment duration of up to ~35 cycles (up to ~2 years [cycle = 3 weeks]). |
IV infusion
其他名称:
IV infusion
其他名称:
IV infusion
其他名称:
IV infusion
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Progression-free Survival (PFS)
大体时间:Up to ~31 months
|
PFS was defined as the time from randomization to the first documented progressive disease (PD) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) based on blinded independent central review (BICR) or death due to any cause, whichever occurs first. PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of one or more new lesions was also considered PD. PFS was analyzed by the non-parametric Kaplan-Meier (K-M) method. The protocol specified final analysis of PFS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Up to ~31 months
|
|
Overall Survival (OS)
大体时间:Up to ~51 months
|
OS was defined as the time from randomization to death due to any cause. OS was analyzed by the non-parametric K-M method. Participants without documented death at the time of analyses were censored at the date of last known to be alive. The protocol specified final analysis of OS is presented here for the first pembrolizumab course in the Maintenance Phase. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Up to ~51 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of Participants Who Experience One or More Adverse Events (AEs)
大体时间:Up to ~5 years
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience one or more AEs will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course. |
Up to ~5 years
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
大体时间:Up to ~5 years
|
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. The protocol specified final analysis will be presented for the first pembrolizumab course. |
Up to ~5 years
|
|
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status / Quality of Life (Items 29 and 30) Scale Score
大体时间:Baseline and Week 24
|
EORTC QLQ-C30 is a questionnaire to assess the overall quality of life (QoL) of cancer patients. Participant responses to questions regarding Global Health Status (GHS; "How would you rate your overall health during the past week?") and QoL ("How would you rate your overall quality of life during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging the raw scores of the 2 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in GHS and QoL combined score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Baseline and Week 24
|
|
Time to True Deterioration (TTD) in EORTC QLQ-C30 Global Health Status / Quality of Life (Items 29 & 30) Scale Score
大体时间:Up to ~24 months
|
EORTC QLQ-C30 is a questionnaire to assess QoL of cancer patients. Participant responses to questions on GHS ("How would you rate your overall health during the past week?") and QoL ("How would you rate your overall QoL during the past week?") are scored on a 7-point scale (1= Very poor to 7=Excellent). The combined score of GHS (Item 29) and QoL (Item 30) is computed by averaging raw scores of the 2 items and applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in GHS-QoL combined score. TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome was not done in the Induction Phase. |
Up to ~24 months
|
|
Change From Baseline in EORTC Quality of Life Questionnaire Lung Cancer Module 13 (QLQ-LC13) Cough (Item 1) Scale Score
大体时间:Baseline and Week 24
|
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 cough (Item 1) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Baseline and Week 24
|
|
TTD in EORTC QLQ-LC13 Cough (Item 1) Scale Score
大体时间:Up to ~24 months
|
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding cough (Item 1): "How much did you cough?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0-100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in cough (Item 1). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Up to ~24 months
|
|
Change From Baseline in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
大体时间:Baseline and Week 24
|
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-LC13 chest pain (Item 10) score is presented. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Baseline and Week 24
|
|
TTD in EORTC QLQ-LC13 Chest Pain (Item 10) Scale Score
大体时间:Up to ~24 months
|
EORTC QLQ-LC13 is a lung cancer specific questionnaire. Participant responses to the question regarding chest pain (Item 10): "Have you had pain in your chest?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in chest pain (Item 10). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Up to ~24 months
|
|
Change From Baseline in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
大体时间:Baseline and Week 24
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. The change from baseline in EORTC QLQ-C30 dyspnea (Item 8) score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Baseline and Week 24
|
|
TTD in EORTC QLQ-C30 Dyspnea (Item 8) Scale Score
大体时间:Up to ~24 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to the question regarding dyspnea (Item 8): "Were you short of breath?" are scored on a 4-point scale (1=Not at All to 4=Very Much). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A lower score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in dyspnea (Item 8). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Up to ~24 months
|
|
Change From Baseline in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
大体时间:Baseline and Week 24
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. The change from baseline in EORTC QLQ-C30 physical functioning (Items 1-5) combined score is presented. The protocol specified final analysis for the first pembrolizumab course in Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Baseline and Week 24
|
|
TTD in EORTC QLQ-C30 Physical Functioning (Items 1 to 5) Scale Score
大体时间:Up to ~24 months
|
EORTC QLQ-C30 is a questionnaire to assess the overall QoL of cancer patients. Participant responses to 5 questions about their physical functioning (Items 1 to 5) are scored on a 4-point scale (1=Not at All to 4=Very Much). The combined score of items 1 to 5 is computed by averaging the raw scores of the 5 items and then applying a linear transformation to standardize the average score, so that the combined scores range from 0-100. A higher score indicates a better outcome. TTD is defined as the time from baseline to first onset of ≥10-point negative change (decrease) from baseline in physical functioning (Items 1 to 5). TTD estimated by non-parametric K-M method is presented here. A longer TTD indicates a better outcome. The protocol specified final analysis for the first pembrolizumab course in the Maintenance Phase is reported. Per protocol, analysis for this outcome measure was not planned or conducted in the Induction Phase. |
Up to ~24 months
|
合作者和调查者
调查人员
- 研究主任:Medical Director、Merck Sharp & Dohme LLC
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 7339-006
- 2018 (美国 NIH 拨款/合同)
- MK-7339-006 (其他标识符:MSD)
- KEYLYNK-006 (其他标识符:MSD)
- 194895 (注册表标识符:JAPIC-CTI)
- 2018-004720-11 (EudraCT编号)
- U1111-1300-7107 (注册表标识符:UTN)
- 2023-509774-40-00 (注册表标识符:EU CT)
- 2023 (美国 NIH 拨款/合同)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.